Cell & Gene Tx


COVID’s Effect on mRNA Assets, Part II: Experience (and Quality) Matters

  With renewed interest in disparate applications and the subsequent flood of newcomers to mRNA asset development, the focus on quality and experience with regard to mRNA is more important

COVID’s Effect on mRNA Assets, Part I: Vaccines & Delivery

  With a global pandemic to fight, the speed, efficacy, and efficiency of mRNA vaccine research, development, and manufacturing have been proven invaluable. While the Moderna (mRNA-1273) and BioNTech (Comirnaty)